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Dr Nguyen. No, I think it is more than just a perturbation of
cell cycle. I think it has something to do with cancer cells’ survival
response to stress.
Dr David H. Harpole, Jr (Durham, NC). Could you go back
to the slide with the graphs of paclitaxel showing the suppressor at
different doses? There was something that was a little confusing to
me.
If I look at the top panels, at the zero time point, it looks like
the fractured cell viability is actually decreased. Those lines are
almost parallel. So what I am trying to say is that by looking at
them myself, I can’t really see that there’s a difference in the
top, middle, and lower panels with respect to the paclitaxel kill,
if you normalize them all at zero time points to the same
baseline. Does that make sense? Because the 3 lines are parallel
to each other, I think what you are showing is the effect of
giving your agent, but I am not sure that it shows a dependence
on paclitaxel.
Dr Nguyen. Right. I do see what you mean. I had to normalize
LY-treated cells alone to calculate paclitaxel IC50 values (indica-
tive of paclitaxel effect in LY-treated cells with exclusion of LY
mild growth inhibitory effect). These graphs are not to scale, so
that’s why they look like that.
Dr Harpole. All right. That explains it. Because at first it didn’t
seem to make sense.
Dr Nguyen. Right. Because if I put the graphs to scale, it is
very hard to demonstrate the point. But once you normalize for that
and calculate out the paclitaxel IC50 values, there is a clear
enhancement of paclitaxel cytotoxicity by LY.
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